智通财经APP讯,科济药业-B(02171)公布2025年中期业绩,收益为5096.1万元,同比增长703.8%;毛利2936.9万元,同比增长约17.16倍;净亏损7548.3万元,同比收窄78.53%;每股亏损0.14元。
公告称,亏损减少主要是由于期内的研发开支减少、行政开支减少、外汇收益净额上升及毛利上升。
智通财经APP讯,科济药业-B(02171)公布2025年中期业绩,收益为5096.1万元,同比增长703.8%;毛利2936.9万元,同比增长约17.16倍;净亏损7548.3万元,同比收窄78.53%;每股亏损0.14元。
公告称,亏损减少主要是由于期内的研发开支减少、行政开支减少、外汇收益净额上升及毛利上升。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.